Adivo
Adivo is a Martinsried, Germany-based veterinary biotechnology company founded in 2012 that develops therapeutic antibodies for pet health. Now a Zoetis subsidiary, it focuses on antibody engineering for animal disease applications.
- Company typePrivate
- Founded2012
- HeadquartersMartinsried, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Adivo does
Adivo is a veterinary biotechnology company headquartered in Martinsried, Germany, founded in 2012 by Kathrin Ladetzki-Baehs. The company specializes in developing therapeutic antibodies for animal health, with a vertical focus on pet therapeutics and antibody-based treatments addressing unmet medical needs in veterinary care. Its business operates as a single-product/core-technology platform centered on species-specific antibody engineering, distinguishing it from generic veterinary medicine approaches.
Prior to its acquisition by Zoetis, Adivo raised early-stage capital from HTGF, MorphoSys, and OCCIDENT in 2018, followed by approximately $2.8 million from the European Innovation Council in 2021. The company maintained a small team of 11–50 employees and operated without disclosed commercial revenue, pricing, or named customers, consistent with a pre-commercial R&D-stage biotech. Its go-to-market and revenue model are not documented in available sources.
Adivo was acquired by Zoetis, the global animal health company, as part of Zoetis's broader strategy to expand into specialized pet therapeutics. The transaction was announced alongside Zoetis's parallel acquisition of PetMedix, signaling a coordinated platform-building move into veterinary biologics. Post-acquisition, Adivo operates as a subsidiary of Zoetis, and its antibody development capability is now embedded within Zoetis's pet therapeutics portfolio serving veterinary markets globally.
Adivo firmographics
Firmographics- Name
- Adivo
- Legal name
- Adivo
- Website
- https://adivo.vet
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Adivo is a Martinsried, Germany-based veterinary biotechnology company founded in 2012 that develops therapeutic antibodies for pet health. Now a Zoetis subsidiary, it focuses on antibody engineering for animal disease applications.
- Ownership category
- akta.pro rank
Adivo industry classification
Industry- Product category
- Veterinary Biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)
- akta.pro secondary industry
- Companion Animal Therapeutics (Rx) (HLAMAEAA)
Keywords
Where Adivo is headquartered
LocationHeadquarters
- HQ city
- Martinsried
- HQ country
- Germany
- HQ region
- Europe
Markets served
Adivo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Adivo product offering
Product offeringCore offering
Adivo develops specialized therapeutic antibodies for pet and animal health applications, addressing unmet medical needs in veterinary care. The company focuses on antibody-based treatments designed specifically for animal diseases and operates as a single-platform antibody development business. Adivo was acquired by Zoetis to expand the parent company's portfolio in specialized pet therapeutics.
Product overview
Adivo is a specialized antibody development company focused on developing therapeutic antibodies for animal health. The company operates as a single-product/core technology business, providing specialized pet therapeutics through its antibody development capabilities. Adivo was acquired by Zoetis, the global animal health company, as part of Zoetis's strategy to expand into specialized pet therapeutics through the acquisition of antibody development companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Therapeutic Antibody Pipeline (Pet Health)
Companies that use Adivo
Customer profileSegments1 record
Ideal customer profiles1 record
Adivo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Adivo partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Adivo competitors and assessment
Company assessmentOthers
- MorphoSys: Human health antibody engineering specialist and prior Adivo investor. Comparable as the antibody technology platform provider whose expertise informs Adivo's therapeutic antibody pipeline.
Broad incumbents
- Elanco Animal Health: Global animal health company with growing companion animal therapeutics portfolio. Competes for the same veterinary biologics opportunities that Adivo's antibody platform targets.
- Virbac: France-based global animal health company with specialty focus on companion animal therapeutics. Comparable as a mid-to-large incumbent pursuing differentiated pet Rx products.
- Zoetis: Global leader in animal health pharmaceuticals and biologics across companion and livestock species. Acquired Adivo and PetMedix specifically to anchor a pet antibody franchise; offers overlapping commercial reach with broader portfolio.
- Boehringer Ingelheim Animal Health: Top-three global animal health company with biologics, vaccines, and pharma for pets and livestock. Comparable as a scaled buyer/competitor in veterinary monoclonal antibody and biologic R&D.
Direct peers
- Aratana Therapeutics: Veterinary biotech focused on innovative therapeutics (including antibodies) for companion animals, later acquired by Elanco. Historically the most direct US analog to Adivo's pet biologics model.
- Kindred Biosciences: US veterinary biotech developing monoclonal antibodies and biologics for companion animal indications (later acquired by Elanco). Direct peer in species-specific antibody development.
- PetMedix: UK-based veterinary biotech developing fully species-specific therapeutic antibodies for companion animals. Acquired alongside Adivo by Zoetis to build out the animal health antibody platform; closest direct peer in modality and target market.
- Invetx: Boston-area animal health biotech engineering species-specific monoclonal antibodies for use in companion animal therapeutics. Direct peer in monoclonal antibody platform focus and veterinary indication portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Adivo social profiles
Digital presenceAdivo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adivo leadership team
Management profileNumber of profiles
Profiles1 record
Adivo funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adivo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adivo
What does Adivo do?
Adivo develops specialized therapeutic antibodies for pet and animal health applications, addressing unmet medical needs in veterinary care. The company focuses on antibody-based treatments designed specifically for animal diseases and operates as a single-platform antibody development business. Adivo was acquired by Zoetis to expand the parent company's portfolio in specialized pet therapeutics.
Is Adivo a public or private company?
Adivo is a private company. It is classified as corporate owned and is currently acquired.
When was Adivo founded?
Adivo was founded in 2012. It employs 11 to 50 people.
Where is Adivo based?
Adivo is headquartered in Martinsried, Germany, in the Europe region.
Who are Adivo's main competitors?
MorphoSys is listed as an others. Broad incumbents are Elanco Animal Health, Virbac, Zoetis and Boehringer Ingelheim Animal Health. Direct peers are Aratana Therapeutics, Kindred Biosciences, PetMedix and Invetx.
Does Adivo have an API?
No public API is recorded for Adivo.
What industry is Adivo in?
Adivo's product category is Veterinary Biotechnology. Its primary akta.pro industry code is HLAMAEAK, Biologics & Immunotherapies (Non-vaccine), with a secondary code of HLAMAEAA, Companion Animal Therapeutics (Rx). Its NAICS code is 325414 and its SIC code is 2836.